Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2023 | Genetic mutations as poor prognostic indicators of HCT in venetoclax-treated AML

Yuho Najima • 11 Dec 2023
ASH 2023
Acute Myeloid Leukemia Leukemia Azacitidine Venetoclax

Yuho Najima, MD, PhD, Komagome Hospital, Tokyo, Japan, discusses the outcomes of hematopoietic cell transplantation (HCT) for acute myeloid leukemia (AML) patients treated with venetoclax-based bridging therapy. Genetic analysis through next-generation sequencing (NGS) identified TP53 and kinase-related gene mutations as poor prognostic indicators, but venetoclax-based therapy was found to enhance outcomes. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Yuho Najima

8:57
Outcomes of SCT in T-ALL and T-LBL
Yuho Najima • 11 Dec 2023

Related Videos

1:40
The role of CPX-351 in the AML treatment landscape & insights into the AMLSG 30-18 trial
Felicitas Thol • 19 Apr 2024
3:21
Integrating genomics and MRD in transplant decision-making for patients with AML
Jurjen Versluis • 22 Apr 2024
4:19
Blinatumomab to achieve remission and consolidation with haploSCT for pediatric ALL
Alberto Olaya-Vargas • 15 Apr 2024
3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals